Total Payments
$1.9M
2024 Payments
$540,566
Companies
14
Transactions
1,515
Medicare Patients
1,942
Medicare Billing
$220,070
Payment Breakdown by Category
Other$1.4M (74.0%)
Consulting$239,381 (12.4%)
Travel$235,215 (12.2%)
Food & Beverage$26,838 (1.4%)
Research$870.43 (0.0%)
Education$13.06 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.4M | 402 | 73.7% |
| Consulting Fee | $239,381 | 99 | 12.4% |
| Travel and Lodging | $235,215 | 622 | 12.2% |
| Food and Beverage | $26,838 | 385 | 1.4% |
| Compensation for serving as faculty or as a speaker for a medical education program | $4,290 | 1 | 0.2% |
| Unspecified | $870.43 | 1 | 0.0% |
| Honoraria | $331.77 | 3 | 0.0% |
| Education | $13.06 | 2 | 0.0% |
Payments by Type
General
$1.9M
1,514 transactions
Research
$870.43
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $603,715 | 453 | $0 (2024) |
| PUMA BIOTECHNOLOGY, INC. | $410,152 | 419 | $0 (2024) |
| Gilead Sciences, Inc. | $222,622 | 136 | $0 (2024) |
| Daiichi Sankyo Inc. | $205,893 | 165 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $192,766 | 114 | $0 (2024) |
| Stemline Therapeutics Inc. | $190,238 | 125 | $0 (2024) |
| Lilly USA, LLC | $63,895 | 59 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $29,856 | 29 | $0 (2024) |
| Eli Lilly and Company | $4,130 | 3 | $0 (2024) |
| Seagen Inc. | $2,534 | 3 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $540,566 | 308 | PFIZER INC. ($153,497) |
| 2023 | $354,600 | 254 | PFIZER INC. ($73,348) |
| 2022 | $289,562 | 216 | PUMA BIOTECHNOLOGY, INC. ($78,822) |
| 2021 | $200,881 | 192 | PUMA BIOTECHNOLOGY, INC. ($72,453) |
| 2020 | $195,819 | 138 | Puma Biotechnology, Inc. ($71,576) |
| 2019 | $137,761 | 152 | Puma Biotechnology, Inc. ($85,350) |
| 2018 | $132,852 | 171 | PFIZER INC. ($103,851) |
| 2017 | $76,362 | 84 | PFIZER INC. ($71,818) |
All Payment Transactions
1,515 individual payment records from CMS Open Payments — Page 1 of 61
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Consulting Fee | Cash or cash equivalent | $2,180.00 | General |
| Category: ONC | ||||||
| 12/12/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,200.00 | General |
| Category: ONC | ||||||
| 12/12/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $150.00 | General |
| Category: ONC | ||||||
| 12/12/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $113.52 | General |
| Category: ONC | ||||||
| 12/12/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $74.39 | General |
| 12/11/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $31.52 | General |
| Category: Oncology | ||||||
| 12/10/2024 | Genentech USA, Inc. | Itovebi (Biological) | Consulting Fee | Cash or cash equivalent | $1,875.00 | General |
| Category: BioOncology | ||||||
| 12/10/2024 | Genentech USA, Inc. | Itovebi (Biological) | Food and Beverage | In-kind items and services | $228.46 | General |
| Category: BioOncology | ||||||
| 12/09/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $117.93 | General |
| Category: Oncology | ||||||
| 12/05/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $9.44 | General |
| Category: ONCOLOGY | ||||||
| 11/28/2024 | PFIZER INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,000.00 | General |
| 11/28/2024 | PFIZER INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,000.00 | General |
| 11/26/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,720.00 | General |
| Category: ONC | ||||||
| 11/25/2024 | PFIZER INC. | IBRANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,125.00 | General |
| Category: ONCOLOGY | ||||||
| 11/21/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,980.00 | General |
| Category: ONC | ||||||
| 11/15/2024 | PFIZER INC. | IBRANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,500.00 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2024 | PUMA BIOTECHNOLOGY, INC. | NERLYNX (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,000.00 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Travel and Lodging | In-kind items and services | $593.22 | General |
| Category: ONC | ||||||
| 11/14/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Travel and Lodging | In-kind items and services | $507.25 | General |
| Category: ONC | ||||||
| 11/14/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Travel and Lodging | In-kind items and services | $468.66 | General |
| Category: ONC | ||||||
| 11/14/2024 | PUMA BIOTECHNOLOGY, INC. | NERLYNX (Drug) | Food and Beverage | Cash or cash equivalent | $61.03 | General |
| Category: ONCOLOGY | ||||||
| 11/12/2024 | Lilly USA, LLC | VERZENIO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,200.00 | General |
| Category: Oncology | ||||||
| 11/12/2024 | Lilly USA, LLC | VERZENIO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,800.00 | General |
| Category: Oncology | ||||||
| 11/12/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Consulting Fee | In-kind items and services | $2,145.00 | General |
| Category: Oncology | ||||||
| 11/12/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $22.20 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| CLEE011O12301C | Novartis Pharmaceuticals Corporation | $870.43 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 549 | 751 | $155,262 | $64,641 |
| 2022 | 5 | 507 | 655 | $119,877 | $58,708 |
| 2021 | 6 | 488 | 621 | $116,141 | $56,696 |
| 2020 | 5 | 398 | 551 | $92,283 | $40,025 |
Total Patients
1,942
Total Services
2,578
Medicare Billing
$220,070
Procedure Codes
35
All Medicare Procedures & Services
35 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 83 | 159 | $33,079 | $16,762 | 50.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 140 | 194 | $34,920 | $12,831 | 36.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 146 | 181 | $32,373 | $12,391 | 38.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 66 | 102 | $21,330 | $10,966 | 51.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 48 | 48 | $16,287 | $6,058 | 37.2% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 27 | 27 | $8,958 | $2,477 | 27.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 15 | 15 | $4,920 | $2,060 | 41.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 13 | 14 | $1,890 | $552.86 | 29.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 11 | 11 | $1,505 | $542.38 | 36.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 141 | 194 | $30,654 | $13,092 | 42.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 64 | 102 | $17,140 | $11,185 | 65.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 72 | 102 | $17,152 | $11,127 | 64.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 122 | 148 | $23,520 | $10,406 | 44.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 48 | 48 | $14,704 | $6,720 | 45.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 18 | 18 | $5,540 | $2,494 | 45.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 16 | 16 | $7,600 | $2,409 | 31.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 12 | 13 | $1,711 | $665.99 | 38.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 14 | 14 | $1,856 | $610.48 | 32.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 82 | 128 | $21,546 | $13,287 | 61.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 125 | 170 | $26,419 | $11,967 | 45.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 72 | 99 | $16,752 | $10,693 | 63.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 87 | 99 | $15,434 | $6,687 | 43.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 43 | 43 | $12,752 | $5,896 | 46.2% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 16 | 17 | $8,123 | $2,528 | 31.1% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 15 | 15 | $4,449 | $2,141 | 48.1% |
About Dr. Anne O'dea, M.D
Dr. Anne O'dea, M.D is a Medical Oncology healthcare provider based in Westwood, Kansas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/25/2007. The National Provider Identifier (NPI) number assigned to this provider is 1043439102.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Anne O'dea, M.D has received a total of $1.9M in payments from pharmaceutical and medical device companies, with $540,566 received in 2024. These payments were reported across 1,515 transactions from 14 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.4M).
As a Medicare-enrolled provider, O'dea has provided services to 1,942 Medicare beneficiaries, totaling 2,578 services with total Medicare billing of $220,070. Data is available for 4 years (2020–2023), covering 35 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Westwood, KS
- Active Since 04/25/2007
- Last Updated 07/21/2022
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1043439102
Products in Payments
- IBRANCE (Drug) $485,680
- NERLYNX (Drug) $306,966
- Trodelvy (Drug) $218,390
- Orserdu (Drug) $179,418
- Enhertu (Drug) $156,865
- Nerlynx (Drug) $102,966
- ENHERTU (Biological) $99,575
- VERZENIO (Drug) $59,854
- ENHERTU (Drug) $48,905
- TALZENNA (Drug) $28,725
- KISQALI (Drug) $19,168
- LYNPARZA (Drug) $14,220
- ELZONRIS (Drug) $7,800
- TUKYSA (Drug) $6,918
- BENEFIX (Biological) $5,000
- PIQRAY (Drug) $3,849
- Itovebi (Biological) $2,103
- Udenyca (Biological) $298.51
- Perjeta (Biological) $48.35
- COBALT DR MRI SURESCAN (Device) $39.90
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Westwood
Weijing Sun, Md, MD
Medical Oncology — Payments: $192,418
Medical Oncology $192,418
Dr. Anwaar Saeed, M.d, M.D
Medical Oncology — Payments: $96,929
Medical Oncology $96,929
Dr. Joaquina Baranda, Md, MD
Medical Oncology — Payments: $29,220
Medical Oncology $29,220
Dr. Robert Tassan, M.d, M.D
Medical Oncology — Payments: $22,156
Medical Oncology $22,156
Stephen Williamson, M.d, M.D
Medical Oncology — Payments: $2,901
Medical Oncology $2,901
Alan Israel, Md, MD
Medical Oncology — Payments: $167.28
Medical Oncology $167.28